BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the third quarter of 2025 and provided a ...
Curonix LLC (“Curonix” or the “Company”), a medical technology company dedicated to developing and commercializing innovative therapies to relieve chronic pain, today announced the appointment of ...
Conference Call and Webcast Information Date: Thursday, November 13, 2025 Time: 4:30 p.m. ET Webcast Link: BioAtla Third Quarter 2025 Earnings Conference Call Dial-in Numbers: (800)-343-4136 (domestic ...
Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has ...
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at A replay of the fireside chat will be available on the Ardelyx ...
A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible ...
PALO ALTO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, a nonprofit medical research organization, today announced the appointment of Kael Reicin to the role of Chief ...
Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory ...
Proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025, including $12 million from the promissory note GARDEN CITY, N.Y., Nov. 05, 2025 ...
Financial Results for the Quarter Ended September 30, 2025 For the quarter ended September 30, 2025, Vera Therapeutics reported a net loss of $80.3 million, or a net loss per diluted share of $1.26, ...
Praxis reported a net loss of $73.9 million for the three months ended September 30, 2025, including $7.4 million of stock-based compensation expense, compared to $51.9 million for the three months ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback